We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Aldeyra Therapeutics Inc
10 own
16 watching
Current Price
$0
$0.13
(1.27%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
626.13M
52-Week High
10.9363
52-Week Low
3.07
Average Volume
0.37M
Dividend Yield
--
P/E Ratio
--
Market Capitalization626.13M52-Week High10.936352-Week Low3.07Average Volume0.37MDividend Yield--P/E Ratio--What does the Aldeyra Therapeutics Inc do?
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company s lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Read More
How much money does Aldeyra Therapeutics Inc make?
News & Events about Aldeyra Therapeutics Inc.
Ticker Report
2 months ago
Aldeyra Therapeutics (NASDAQ:ALDX Get Rating) had its price target lifted by Citigroup from $23.00 to $28.00 in a research report sent to investors on Friday, The Fly reports. A number of other equities analysts have also recently commented on the stock. HC Wainwright reiterated a buy rating...
Benzinga
2 months ago
read more...
Zolmax
3 months ago
Aldeyra Therapeutics, Inc (NASDAQ:ALDX Get Rating) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,020,000 shares, an increase of 19.5% from the January 15th total of 1,690,000 shares. Based on an average ...
Ticker Report
3 months ago
Aldeyra Therapeutics, Inc (NASDAQ:ALDX Get Rating) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 2,020,000 shares, a growth of 19.5% from the January 15th total of 1,690,000 shares. Approximately 3.6% of the shares of the...
Frequently Asked Questions
Frequently Asked Questions
What is Aldeyra Therapeutics Inc share price today?
Can Indians buy Aldeyra Therapeutics Inc shares?
How can I buy Aldeyra Therapeutics Inc shares from India?
Can Fractional shares of Aldeyra Therapeutics Inc be purchased?
What are the documents required to start investing in Aldeyra Therapeutics Inc stocks?
What is today’s traded volume of Aldeyra Therapeutics Inc?
What is today’s market capitalisation of Aldeyra Therapeutics Inc?
What is the 52-Week High and Low Range of Aldeyra Therapeutics Inc?
What percentage is Aldeyra Therapeutics Inc down from its 52-Week High?
What percentage is Aldeyra Therapeutics Inc up from its 52-Week Low?
Current Price
$0
$0.13
(1.27%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.